Skip to content
Review Open access

Prediction of blood-brain barrier permeability using modified poly(dimethylsiloxane).

Aug 2026 · Analytical Methods · Vol 18, pp. 8394-8401 · 0 citations · 34 references
Medicine

TL;DR

It is proposed that analysing permeation of novel pharmaceutical compounds using the DPPC-coated PDMS can help researchers predict BBB permeation using an in vitro technique thus facilitating prediction and helping understand drug behaviour in the body.

Abstract

Blood-brain barrier (BBB) permeability of drugs is fundamental to understand yet incredibly difficult to measure, or even, predict. This study proposes the adoption of a chemically modified form of poly(dimethylsiloxane) (PDMS) as an in vitro biomedical mimic of the BBB for pharmaceutical analysis. Initially, a series of untreated PDMS membrane thicknesses (0.02 to 0.4 mm) were studied to review the permeation of 15 model compounds to ultimately select the most suitable material for further modification. This was deemed to be 0.2 mm for maximising permeability range, maintaining experimental ease of use and also similarity to in vivo BBB thickness. Five distinct membranes were then created and subsequently analysed with the same 15 compounds to determine the most suitable BBB mimic through correlation with literature data. Ultimately, a strong correlation was found between published BBB values and cumulative permeation through the hydrophobic DPPC-coated form of PDMS (r2 = 0.75) based on its similarity to the lipid-rich BBB environment. This then facilitated prediction of BBB values for compounds where no literature data has ever been listed. It is proposed that analysing permeation of novel pharmaceutical compounds using the DPPC-coated PDMS can help researchers predict BBB permeation using an in vitro technique thus facilitating prediction and helping understand drug behaviour in the body.

Read PDF

Similar papers

Open access Nov 2026

Parametric Study to Optimize the Cultivation Conditions of Blood–Brain Barrier Models for In Vitro Drug Testing

Background/Objectives: The permeation behavior of new drug candidates for central nervous system (CNS) diseases is a major bottleneck in drug development. Thus, using a meaningful in vitro blood–brain barrier (BBB) model in the preclinical phase to determine cerebral drug bioavailability is crucial. However, due to the...

Verena Ledwig, T. May, Andreas Dietzel et al. · 0 citations
Open access Oct 2026

Human Skin Permeability Prediction by Machine Learning for Transdermal Drug Delivery

Lipophilicity shows a saturating relationship with skin permeability that a linear equation cannot represent, and interpolation within the sampled chemical space does not imply generalisation to a new therapeutic class.

Seunghwan Oh, S. Ahn · 0 citations
Open access Sep 2026

Unconventional Molecular Descriptors for Blood-Brain Barrier Permeability Prediction: A Unified Model and Its Implications for Local Anesthetic Design, Micellar Formulation, and Chelation-Based Effect Modification.

BACKGROUND Predicting blood-brain barrier (BBB) permeability remains a central problem in central nervous system (CNS) drug design. Conventional rules such as Lipinski's rule of five and related CNS guidelines describe physicochemical boundaries but do not guarantee permeability. OBJECTIVE We examined how a set of mo...

Tatsuki Onishi · 0 citations
Open access Sep 2026

An Integrated Experimental-Computational Platform for Evaluating Blood-Brain Barrier Permeability of Novel Kynurenic Acid Derivatives.

An integrated platform linking molecular structure, physicochemical properties, and BBB permeability to support the rational evaluation and prioritisation of compounds within the investigated KYNA derivative series is established.

Zahraa Ali, Bálint Lőrinczi, Péter Simon et al. · 0 citations
Review Open access Nov 2026

Shape as an Independent Design Parameter for Blood–Brain Barrier Crossing: Anisotropic Nanoparticles in Neurodegenerative Diseases

Background: Neurodegenerative diseases (NDDs) impose a growing burden, yet effective therapy remains limited because the blood–brain barrier (BBB) restricts CNS drug delivery. Existing reviews treat particle geometry as secondary to composition, size, and surface functionalization. Objectives: This review examines shap...

E. Turovsky · 0 citations
Open access Oct 2026

Detachable Modular Blood–Brain Barrier-on-a-Chip with a Concentration Gradient Generator for Stepwise Inflammation Modeling and Drug Evaluation

Background/Objectives: The blood–brain barrier (BBB) is compromised in many neurological disorders, yet in vitro models rarely reproduce graded inflammatory stimulation of brain endothelial cells in vivo. This study developed a detachable, modular BBB-on-a-chip for stepwise inflammation modeling with multi-marker reado...

Ze-Zhi Li, Hai-Zhu Meng, Xin-Meng Liao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.